Neither Saxenda nor Wegovy was ever dispensed within the benefit, whereas Bydureon, Byetta, Lyxumia, Rybelsus, and Suliqua were always claimed to be dispensed within the benefit (see Table 8 in the Appendix)
Levy J, Atkinson AB, Bell PM, McCance DR, Hadden DR
Fragment (176191) is a modified C-terminal fragment of human growth hormone, while CJC-1295 (No DAC) is a growth hormonereleasing hormone (GHRH) analog and Ipamorelin is a selective growth hormone secretagogue receptor (GHS-R) agonist
Clinical trials showed that patients taking GLP-1 drugs experienced significant improvements in blood glucose levels and modest weight loss as a secondary benefit
You have a triple agonist with the strongest single-compound weight-loss record in modern obesity research, plus an amylin analog with a standalone double-digit result and a phase 3 combination precedent proving amylin adds to GLP-1